Efficacy and Safety of SGLT-2 inhibitor to break loose from glucose toxicity and to withdraw insulin therapy in type 2 diabetic inpatients
Not Applicable
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000013539
- Lead Sponsor
- Shiga University of Medical Science Department of Internal Medicine Division of Diabetology, Nephrology, Neurology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1.age <20, >=75 2.BMI <22 kg/m2 3.eGFR <45 ml/min/1.73m2 4. anti-GAD antibody titer >=10 or insulin-dependent 5. patients who have anemia (Hb male <12 g/dl, female <11 g/dl) 6. patients who have cancer, or infection 7. patients judged to be disqualified to this research by physicians
Study & Design
- Study Type
- Interventional,observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method